Nisa投资顾问大大增加了Cidara的股权,但公司损失了钱,COO出售了股票。 Nisa Investment Advisors vastly increased its Cidara stake, but the company lost money and its COO sold shares.

Nisa投资顾问有限公司将其在Cidara治疗方面的股份增加了4,898.5%,在Q3增加了4,898.5%,拥有6,748股,价值646,000美元,而KLP Kapitalfortvalting AS公司增加了2,500股。 Nisa Investment Advisors LLC boosted its stake in Cidara Therapeutics by 4,898.5% in Q3, owning 6,748 shares worth $646,000, while KLP Kapitalforvaltning AS added 2,500 shares. 该公司报告每季度每股损失1.43美元,低于预期。 The company reported a quarterly loss of $1.43 per share, below expectations. COO Shane Ward在12月10日出售了9 959股,净额为219万美元,股份减少了28.46%。 COO Shane Ward sold 9,959 shares on December 10, netting $2.19 million and reducing his stake by 28.46%. 开发抗真菌药物雷扎丁的Cidara公司的市场市值为696亿美元, 目标156.11美元, 获得"持有"评级. Cidara, developing the antifungal rezafungin in late-stage trials, has a market cap of $6.96 billion and a consensus "Hold" rating with a $156.11 target. 机构投资者持有35.82%的股份,内部投资者占3.89%。 Institutional investors hold 35.82% of shares, insiders 3.89%.